NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (251)	12/11/1997 8:32:00 PM
From: Miljenko Zuanic	Read Replies (1) of 328

Peter: From the last conference call NXTR CEO projected 3-3.5 M in revenue from costumer manufacturing. I am glad to see that NXTR is incorporating chemical engineering/advance chemistries in their drug delivery/drug development platform. Getting extra bucks from PASS at early stage is very positive. However, if their technology in batch-type biomacromolecules/intermediates manufacturing is as good as they claim, there will be more than few bucks in future. >>I think (hope) the reduced toxicity will provide sufficient incentive for doctors to use it even though it will be more expensive.<< In P VI post-marketing study Fujisawa will tried to prove that AmBisome, more expensive per mg/dose than Ampho.B, will be equal or less expensive per therapy cycle. Will see will they have success on this one! mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next